Siga Technologies Earnings Call: Cash-Rich, Orders Ahead

Siga Technologies ((SIGA)) has held its Q1 earnings call. Read on for the main highlights of the call.

Siga Technologies’ latest earnings call struck a cautiously optimistic tone, as management balanced sizeable cash reserves and visible near-term orders against a weak first quarter and regulatory friction in Europe. Executives emphasized strong liquidity, continued government backing, and a growing international footprint as reasons to look past quarterly noise.

Strong liquidity and balance sheet

Siga closed the first quarter with roughly $146 million in cash and no debt, giving the company a sizable cushion despite a small loss. Even after paying out a sizable special dividend, management expects pro forma cash to remain above $100 million, preserving flexibility for operations, R&D, and potential strategic moves.

Shareholder return via special dividend

The company declared and paid a special cash dividend of $0.60 per share, its fifth consecutive annual special payout. Management framed the move as a direct signal of confidence in the durability of its balance sheet and cash-generating capacity, even in a year marked by uneven product deliveries.

Near-term revenue visibility from Q2 deliveries

After a quiet first quarter, revenue should step up in the second quarter as Siga expects about $13 million of oral TPOXX deliveries to an international customer. Additional IV TPOXX shipments to the U.S. Strategic National Stockpile are also slated, giving investors clearer near-term visibility into product revenue contributions.

International expansion and Hikma partnership

International momentum featured prominently as the company highlighted a $13 million oral TPOXX order from an Asia-Pacific country scheduled for Q2 delivery. Siga also signed an exclusive license and distribution deal with Hikma MENA FZE to register and commercialize TPOXX across the Middle East and North Africa, while remaining the sole manufacturer.

Pipeline progress in pediatric and PEP programs

R&D updates focused on broadening TPOXX’s clinical reach, with a pediatric IND filed and a Phase 1 pediatric study now underway. The company also reported progress on its post-exposure prophylaxis pathway, with CDC immunogenicity analyses ongoing and an FDA submission for a PEP indication targeted within the next year.

Continued government engagement and funding support

Management underscored steady ties with U.S. health authorities, pointing to $27 million in 2025 funding for pediatric formulation work and IV TPOXX technology transfer. A 2025 IV order and alignment of oral TPOXX pricing and domestic production with federal preparedness priorities reinforced Siga’s role in the national biodefense ecosystem.

Quarterly revenue variability and soft Q1

The first quarter was notably light on deliveries, underlining the inherently lumpy nature of Siga’s business model. Q1 product revenue came mainly from about $1 million of IV TPOXX deliveries to the stockpile and around $2 million of manufacturing reimbursement, supplemented by roughly $3 million in R&D revenue.

Reported losses for the quarter

With minimal shipments, the company posted a pretax operating loss of about $5 million and a net loss near $3 million for the three months ended March 31, 2026. Fully diluted loss per share was $0.05, a reminder that earnings can swing sharply depending on the timing of large government and international orders.

Regulatory setback on European MPOXX indication

On the regulatory front, Siga faced a known headwind as European authorities recommended withdrawing the MPOXX indication. While the committee reaffirmed a positive benefit-risk profile for tecovirimat in treating smallpox, cowpox, and vaccinia complications, the MPOXX withdrawal adds extra implementation work and removes a potential source of label-driven demand.

Slower progress toward new U.S. contract

Investors also heard that negotiations toward a new U.S. government contract are advancing more slowly than in past cycles, creating uncertainty around order timing. Management stressed ongoing dialogue with federal stakeholders but acknowledged that the pace could weigh on near-term visibility for domestic TPOXX volumes.

Limited transparency on Hikma deal economics

While the Hikma MENA partnership could open a large regional market, Siga kept the financial terms confidential, limiting insight into potential upside. Executives noted that additional payments may be triggered under certain conditions, but investors will need to wait for actual orders to gauge margin and revenue impact.

Forward-looking guidance and outlook

Looking ahead, Siga reiterated that results should be evaluated over multi-year periods rather than single quarters due to delivery volatility. Guidance calls for roughly $13 million of oral TPOXX revenue plus additional IV shipments in Q2, ongoing 2025-funded pediatric and IV work, pediatric Phase 1 data in the second half of 2026, and a planned PEP FDA filing within 12 months.

Siga’s earnings call painted a picture of a company with solid financial footing, growing international reach, and a maturing pipeline offset by episodic revenues and regulatory speed bumps. For investors willing to tolerate quarter-to-quarter noise, the long-term thesis rests on sustained government relationships, expanded indications, and the conversion of new global partnerships into recurring sales.